Trials / Unknown
UnknownNCT04941079
Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Immune-related Myopathy (Myasthenia Gravis and Inflammatory Myopathy) Patients ：a Prospective Observational Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 70 (estimated)
- Sponsor
- First Affiliated Hospital of Chongqing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is a prospective observational study. We aim to investigate the safety and efficacy of inactivated SARS-CoV-2 vaccine between immune-related myopathy (myasthenia gravis and inflammatory myopathy) patients and health controls. The main study factors include adverse events following immunization (AEFI), serum specific antibody (Acetylcholine receptor (AChR) antibody, Anti-MuSK (muscle-specific kinase) antibody, myositis antibody) and virus neutralizing antibody titers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | no intervention | no intervention |
Timeline
- Start date
- 2021-06-30
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2021-06-28
- Last updated
- 2021-06-28
Source: ClinicalTrials.gov record NCT04941079. Inclusion in this directory is not an endorsement.